Damae Medical, a Paris, France-based medtech company, closed a €2m funding.
Backers included Kurma Partners, Idinvest Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures, and private investors.
The company intends to use the funds to finance the development and CE marking of OCTAV®, which is scheduled for mid-2018.
Founded in September 2014 by Anaïs Barut, CEO, Damae Medical aims to provide dermatologists with a novel, in vivo imaging technology for a deep look into the skin. This technology enables cellular-resolution imaging of the skin similar to histology, without the need for tissue excision and processing. The company’s lead product, OCTAV®, aimed at the instant, non-invasive diagnosis of skin cancers, is currently tested at the CHU of Saint Etienne.
The technology developed by DAMAE Medical is a new approach of Optical Coherence Tomography (OCT), an imaging modality based on low coherence interferometry.
Infrared light is directed at the skin of the patient and is partially reflected by the internal microstructures of the tissue. This reflected light is mixed with a reference beam of light to produce an interference pattern that is detected by a camera and converted to a cross-sectional image.
The morphology of the tissue can be visualized in real-time at the cellular level up to a depth of about 1 mm below the surface of the skin.
Contact
DAMAE Medical
28, Rue de Turbigo
75003 Paris
+33 (1) 44 49 04 10
info@damaemedical.fr
Follow us on Linkedin!
You must be logged in to post a comment.